|

[SGLTi + previously taken RAAS blocker] Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • National Medical Research Center for Cardiology, Ministry of Health of Russian Federation1

Indications

  • LVDD1
  • HFpEF1
  • Myocardial Fibrosis1
  • Heart Disease1

Other1 trial

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.